TTP 4000

Drug Profile

TTP 4000

Alternative Names: TTP4000

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Oct 2011 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (SC) (NCT01548430)
  • 12 Aug 2009 Preclinical development is ongoing in USA
  • 21 Sep 2006 TransTech Pharma and Pfizer have entered into an license agreement for the development and commercialisation of RAGE modulators worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top